Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
1491results about "Boron compound active ingredients" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Combinations and modes of administration of therapeutic agents and combination therapy
The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.
Owner:ABRAXIS BIOSCI LLC
Boron-containing small molecules
ActiveUS20060234981A1Growth inhibitionAvoid infectionAntibacterial agentsBiocideFungal microorganismsTopical treatment
This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and / or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.
Owner:ANACOR PHARMA INC
Boron-containing small molecules
This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and / or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.
Owner:ANACOR PHARMA LLC
Methods for the identification, assessment, and treatment of patients with cancer therapy
ActiveUS20060281122A1Reduced growth rateEliminate ineffective or inappropriate therapeutic agentsMechanical/radiation/invasive therapiesMicrobiological testing/measurementAbnormal tissue growthRegimen
The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and / or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and / or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
Owner:MILLENNIUM PHARMA INC
Boron-containing small molecules
Owner:ANACOR PHARMA INC
Boron-Containing Small Molecules as Anti-Inflammatory Agents
Owner:ANACOR PHARMA INC
Compounds for the Treatment of Periodontal Disease
Compounds, compositions and methods are provided which are useful in the treatment of periodontal disease.
Owner:ANACOR PHARMA INC
Boron-containing small molecules
This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and / or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.
Owner:ANACOR PHARMA INC
Formulation of boronic acid compounds
The present invention provides stable compounds prepared from boronic acid and lyophilized compounds thereof of the formula (1): in which Z1 and Z2 are moieties derived from sugar. The invention also provides methods for preparing such compounds. Lyophilizing a mixture comprising a boronic acid compound and a moiety derived from sugar produces a stable composition that readily releases the boronic acid compound upon reconstitution in aqueous media.
Owner:US DEPT OF HEALTH & HUMAN SERVICES
Treatment of protein degradation disorders
ActiveUS20060239909A1Augmenting protein stressReduce sensitivityCompounds screening/testingBiocideProteasome degradationCompound (substance)
The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to methods and pharmaceutical compositions for treating multiple myeloma. New HDAC / TDAC inhibitors and aggresome inhibitors are also provided as well as synthetic methodologies for preparing these compounds.
Owner:DANA FARBER CANCER INST INC +1
Composition for promoting healthy bone structure
InactiveUS6447809B1Increase bone densityPrevents radial bone lossBiocideHeavy metal active ingredientsVitamin CRegimen
A dietary supplement for benefitting human bone health includes a calcium source, a source of vitamin D activity, and an osteoblast stimulant. A preferred calcium source is microcrystalline hydroxyapatite, which also contains protein (mostly collagen), phosphorus, fat, and other minerals. A preferred source of vitamin D activity is cholecalciferol, and a preferred osteoblast stimulant is ipriflavone. In addition to these basic ingredients, the composition can further include various other minerals known to occur in bone, vitamin C, and glucosamine sulfate, all of which exert beneficial effects on growth and maintenance of healthy bone. A method for benefitting human bone health involves administering a daily regimen of the dietary supplement.
Owner:PHOENIX DICHTUNGSTECHN +1
Aryl and heteroaryl compounds, compositions and methods of use
InactiveUS20050049310A1Reduce hypoxiaInduce red blood cell productionBiocideOrganic chemistryArylErythropoietin receptor
This invention provides aryl and heteroaryl compounds of Formula (I) as described herein, and methods of their preparation. Also provided are pharmaceutical compositions made with the compounds of Formula (I) and methods for making such compositions. The compounds of Formula (I) may activate an erythropoietin receptor and thus, may be useful to induce red blood cell production. The compounds of Formula (I) and compositions including compounds of Formula (I) may be useful in a variety of applications including the management, treatment and / or control of diseases caused at least in part by deficient (or inefficient) EPO production relative to hemoglobin level.
Owner:VTV THERAPEUTICS LLC
Combination treatment of cd38-expressing tumors
ActiveUS20100092489A1Good curative effectImprove survivalBoron compound active ingredientsSkeletal disorderAntiendomysial antibodiesOncology
The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non- corticosteroid chemotherapeutic agent.
Owner:GENMAB AS
Method of regulating glucose metabolism, and reagents related thereto
InactiveUS20030153509A1Reduce insulin resistanceExcellent hostBiocideDipeptide ingredientsAcute hyperglycaemiaChylomicron
The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and / or atherosclerosis.
Owner:1149336 ONTARIO +2
Boron-containing small molecules
InactiveUS20100256092A1Prevent bacterial growthInhibiting β-lactamaseAntibacterial agentsBiocideBoron containingSmall molecule
Owner:ANACOR PHARMA INC +1
Novel compounds that inhibit dipeptidyl peptidase (DPP-IV) and neprilysin (NEP) and/or angiotensin converting enzyme (ACE)
This invention relates to novel compounds, compositions containing the compounds, that inhibit dipeptidyl peptidase (especially DPP-IV) and neprilysin (NEP, neutral endopeptidase) as well as dipeptidyl peptidase (especially DPP-IV) and angiotensin converting enzyme (ACE) and / or dipeptidyl Peptidase (especially DPP-IV) and vasopeptidases (especially ACE and NEP). These compounds and pharmaceutical compositions thereof are useful for the treatment as well as the prevention of type 2 diabetes mellitus.
Owner:MORPHOCHEM AG
Beta-lactamase inhibitors
InactiveUS20140194386A1Modulate activityUseful in treatmentAntibacterial agentsBiocideOrganic chemistryBeta-Lactamase Inhibitors
Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
Owner:VENATORX PHARMA INC
Boron-containing small molecules
Owner:ANACOR PHARMACEUTICALS LLC
Anti-tumor agents
InactiveUS6890904B1Prevent proliferationMinimize potentialDipeptide ingredientsTetrapeptide ingredientsAbnormal tissue growthLymphatic Spread
A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.
Owner:DARA BIOSCI
Beta-lactamase inhibitors
InactiveUS20100292185A1Reduce bacterial resistanceAntibacterial agentsSilicon organic compoundsStereochemistryBeta-Lactamase Inhibitors
Disclosed herein are α-aminoboronic acids and their derivatives which act as inhibitors of beta-lactamases. Also disclosed herein are pharmaceutical compositions comprising α-aminoboronic acids and methods of use thereof.
Owner:NOVARTIS INT PHARM LTD
Methods for treating diabetes
InactiveUS20060063719A1Reducing blood glucoseLower blood sugar levelsBiocideDipeptide ingredientsPhysiologyType 2 diabetes
Owner:POINT THERAPEUTICS
Boron-containing small molecules
Owner:ANACOR PHARMACEUTICALS LLC
Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent
The present invention provides a novel composition of matter comprised of a mixture of two specific classes of compounds—Free-B-ring flavonoids and flavans—for use in the prevention and treatment of diseases and conditions mediated by the COX-2 and 5-LO pathways. The present invention further provides a novel method for simultaneously inhibiting the cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO) enzymes, and reducing cox-2 mRNA production. Finally, the present invention includes a method for weight loss and blood glucose control. The methods of this invention are comprised of administering to a host in need thereof an effective amount of the composition of this invention together with a pharmaceutically acceptable carrier. This invention relates generally to the prevention and treatment of diseases and conditions mediated by the cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO) pathways, including but not limited to the relief joint discomfort and pain associated with conditions such as osteoarthritis, rheumatoid arthritis, and other injuries that result from overuse.
Owner:UNIGEN
Compounds for enzyme inhibition
InactiveUS20070105786A1Inhibiting and reducing HIV infectionAffecting levelBiocideNervous disorderEnzyme inhibitionAziridine
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles
Owner:ONYX THERAPEUTICS
Beta-lactamase inhibitors
Disclosed herein are α-aminoboronic acids and their derivatives which act as inhibitors of beta-lactamases. Also disclosed herein are pharmaceutical compositions comprising α-aminoboronic acids and methods of use thereof.
Owner:NOVARTIS INT PHARM LTD +1
Biaryl compounds as serine protease inhibitors
InactiveUS6699994B1Organic chemistryPeptide/protein ingredientsSerine Protease InhibitorsFactor VIIa
Owner:BIOCRYST PHARM INC
Boron-based wood preservatives and treatment of wood with boron-based preservatives
InactiveUS20050013939A1Safe handlingConvenient treatmentBiocideBoron compound active ingredientsAlcoholPreservative
A process for treating wood comprising applying to the surface of the wood a boron based preservative which reacts with moisture within the wood to form a boron compound and alcohol and subjecting the wood with the applied preservative to a substantially moisture-free and enclosed environment for a period sufficient for the applied preservative to be absorbed into the wood and to produce the boron compound on reaction with the moisture in the wood and for the alcohol by-product of the reaction to be adsorbed within the wood structure.
Owner:UNIVERSITY OF MELBOURNE
Methods and compositions for treating proliferative diseases
The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.
Owner:ABRAXIS BIOSCI LLC
Boron-containing small molecules as anti-inflammatory agents
Owner:ANACOR PHARMA INC
Eponemycin and epoxomicin analogs and uses thereof
InactiveUS20050101781A1Useful in treatmentBiocidePeptide/protein ingredientsPharmaceutical drugOncology
The present invention provides compounds haviang formula (1): wherein R1-R6, A, J, D, E, G, Q, w, x, y, and z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of cancer and / or inflammatory disorders, and more generally as proteasome inhibitors.
Owner:EISIA R&D MANAGEMENT CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com